Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the Philips ECG AI Marketplace, a platform that gives cardiac care teams access to multiple vendor offerings all in one central location to help clinicians manage and implement AI-powered diagnostic tools more easily.

Royal Philips（纽约证券交易所代码：PHG，阿姆斯特丹证券交易所代码：PHIA），全球健康技术领域的领导者，今天宣布推出飞利浦心电图AI市场平台。该平台为心脏护理团队提供了一个集中位置，可以访问多家供应商的产品，帮助临床医生更轻松地管理和实施基于人工智能的诊断工具。

, an AI-driven health technology company committed to transforming the continuum of cardiac care, is the first organization to leverage Philips’ platform. Its FDA-cleared ECG-AI™ LEF (Low Ejection Fraction) algorithm will be available in the Philips ECG AI Marketplace.

，一家致力于改变心脏护理全过程的AI驱动健康技术公司，是第一家利用飞利浦平台的组织。其获得FDA认证的ECG-AI™ LEF（低射血分数）算法将在飞利浦心电图AI市场中提供。

As clinicians become more comfortable using AI-powered tools, healthcare organizations have adopted multiple vendors’ platforms and solutions. The Philips ECG AI Marketplace enables U.S. hospitals and health systems to integrate validated algorithms into their workflow and existing Philips infrastructure.

随着临床医生越来越习惯使用人工智能工具，医疗保健机构已经采用了多个供应商的平台和解决方案。飞利浦心电图人工智能市场使美国的医院和卫生系统能够将经过验证的算法整合到他们的工作流程和现有的飞利浦基础设施中。

The Marketplace also gives cardiac care teams direct access to a broad portfolio of AI tools at the point of care, helping reduce the time it takes for clinicians to review ECG results and fast-track diagnoses for patients. The platform’s ability to manage vendor connections for each AI solution also improves operational costs and efficiency by removing the need to devote hospital IT resources to overseeing the different interfaces for every tool. .

市场平台还让心脏护理团队在诊疗时直接获取广泛的 AI 工具组合，有助于缩短临床医生查看心电图结果的时间，并加快患者的诊断速度。该平台管理每个 AI 解决方案供应商连接的能力，还通过消除投入医院 IT 资源来监管每个工具的不同接口需求，降低了运营成本并提高了效率。

“Through the Philips ECG AI Marketplace, we’re building a more flexible and connected approach to innovation in cardiac care,” said Stefano Folli, Business Leader, Ambulatory Monitoring and Diagnostics, Philips. “The Philips ECG AI Marketplace meets a growing need for easier access and management of AI-enabled tools to improve the healthcare experience for clinicians and patients.

“通过飞利浦心电图 AI 市场平台，我们正在构建一种更灵活、更互联的心脏护理创新方法，”飞利浦公司业务负责人斯特凡诺·福里 (Stefano Folli) 表示，“飞利浦心电图 AI 市场平台满足了人们对更便捷地获取和管理启用 AI 的工具的日益增长的需求，从而改善临床医生和患者的医疗体验。

Our collaboration with Anumana is a strong example of how these tools can support both earlier detection of heart diseases and accelerate patient care.”.

我们与Anumana的合作是一个有力的例子，展示了这些工具如何能够支持更早期的心脏病检测并加速患者护理。

Anumana’s FDA breakthrough-designated LEF algorithm is now integrated across Philips’ ECG portfolio through the Philips ECG AI Marketplace, including IntelliSpace ECG and Philips cardiographs. The LEF algorithm analyzes a standard 12-lead resting ECG to identify reduced ejection fraction, an early indicator of heart failure.

Anumana的获得FDA突破性设计指定的LEF算法现已通过飞利浦ECG AI市场集成到飞利浦的ECG产品组合中，包括IntelliSpace ECG和飞利浦心电图仪。该LEF算法分析标准的12导联静息心电图，以识别射血分数降低，这是心力衰竭的早期指标。

With Anumana’s algorithm now available through the Philips ECG AI Marketplace, healthcare providers can access AI-powered cardiac insights during routine ECG ordering and interpretation, supporting timely and informed care..

通过飞利浦心电图 AI 市场可以获得 Anumana 的算法，医疗保健提供者在常规心电图订购和解读过程中可以获取人工智能驱动的心脏洞察，支持及时且明智的护理。

“We’re proud to be the flagship offering on the Philips ECG AI Marketplace,” said Simos Kedikoglou, MD, President and Chief Operating Officer at Anumana. “Working with Philips expands access to our ECG-AI technology through a trusted platform, starting with our cleared LEF algorithm and extending to our full suite of point-of-care algorithms as they receive FDA regulatory clearance.

“我们很自豪能成为飞利浦心电图人工智能市场平台上的旗舰产品，”Anumana公司总裁兼首席运营官西莫斯·凯迪科格鲁医学博士表示，“与飞利浦的合作通过一个可信赖的平台扩大了我们心电图人工智能技术的使用范围，首先是我们已获批的左心室功能障碍（LEF）算法，并随着我们的全套即时诊疗算法获得FDA监管批准后逐步扩展。”

Anumana’s AI algorithms, including for LEF detection, have been extensively evaluated in studies involving more than 150,000 patients and are supported by nearly 100 peer-reviewed publications. By making early detection tools available across multiple platforms, this collaboration helps clinicians intervene sooner, reflecting a shared commitment to improving outcomes for patients at risk of heart failure.”.

Anumana的AI算法，包括用于左心室功能障碍（LEF）检测的算法，已经在涉及超过15万名患者的研究中得到了广泛评估，并得到了近100篇同行评审出版物的支持。通过在多个平台上提供早期检测工具，这项合作有助于临床医生更早进行干预，体现了对改善心力衰竭风险患者预后的共同承诺。"

The collaboration with Anumana is part of the continuing expansion by Philips to open its ECG ecosystem to third-party solutions, to ease integration and support clinical decision-making. By making AI diagnostics more available to cardiac care teams, Philips aims to improve access to early cardiovascular disease detection and care..

与Anumana的合作是飞利浦持续扩展的一部分，旨在将其心电图生态系统开放给第三方解决方案，以简化集成并支持临床决策。通过使人工智能诊断更易于为心脏护理团队使用，飞利浦旨在改善对心血管疾病早期检测和护理的获取途径。

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home..

皇家飞利浦（NYSE: PHG, AEX: PHIA）是一家领先的健康技术公司，专注于通过有意义的创新来改善人们的健康和福祉。飞利浦以患者和人民为中心的创新利用先进技术，并结合深入的临床和消费者洞察，为消费者提供个人健康解决方案，为医疗机构及其患者提供专业的医疗解决方案，涵盖医院和家庭场景。

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries.

总部位于荷兰的飞利浦是诊断影像、超声、影像引导治疗、监测和企业信息学以及个人健康领域的领导者。2024年销售额达180亿欧元，在全球100多个国家拥有约67,200名员工，负责销售和服务。